92 related articles for article (PubMed ID: 11333782)
21. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
[TBL] [Abstract][Full Text] [Related]
22. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
Bauerschmitz GJ; Barker SD; Hemminki A
Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
[TBL] [Abstract][Full Text] [Related]
23. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
[TBL] [Abstract][Full Text] [Related]
25. Therapy of cancer by cytokines mediated by gene therapy approach.
Qian C; Liu XY; Prieto J
Cell Res; 2006 Feb; 16(2):182-8. PubMed ID: 16474432
[TBL] [Abstract][Full Text] [Related]
26. [Brain tumors].
Hatano M; Mizuno M; Yoshida J
Gan To Kagaku Ryoho; 2003 Apr; 30(4):455-9. PubMed ID: 12722674
[TBL] [Abstract][Full Text] [Related]
27. Targeting gene-virotherapy of cancer and its prosperity.
Liu XY
Cell Res; 2006 Nov; 16(11):879-86. PubMed ID: 17102812
[TBL] [Abstract][Full Text] [Related]
28. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy.
Idema S; Lamfers ML; van Beusechem VW; Noske DP; Heukelom S; Moeniralm S; Gerritsen WR; Vandertop WP; Dirven CM
J Gene Med; 2007 Dec; 9(12):1046-56. PubMed ID: 17966130
[TBL] [Abstract][Full Text] [Related]
29. [Gene therapy and molecular therapeutic for head and neck cancer].
Tanaka H
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2046-51. PubMed ID: 16352927
[TBL] [Abstract][Full Text] [Related]
30. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
Conrad C; Miller CR; Ji Y; Gomez-Manzano C; Bharara S; McMurray JS; Lang FF; Wong F; Sawaya R; Yung WK; Fueyo J
Cancer Gene Ther; 2005 Mar; 12(3):284-94. PubMed ID: 15650766
[TBL] [Abstract][Full Text] [Related]
31. Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status.
Bourbeau D; Lavoie G; Nalbantoglu J; Massie B
J Gene Med; 2004 Dec; 6(12):1320-32. PubMed ID: 15515126
[TBL] [Abstract][Full Text] [Related]
32. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
Ganesh S; Gonzalez Edick M; Idamakanti N; Abramova M; Vanroey M; Robinson M; Yun CO; Jooss K
Cancer Res; 2007 May; 67(9):4399-407. PubMed ID: 17483354
[TBL] [Abstract][Full Text] [Related]
33. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
34. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors.
Abe T; Wakimoto H; Bookstein R; Maneval DC; Chiocca EA; Basilion JP
Cancer Gene Ther; 2002 Mar; 9(3):228-35. PubMed ID: 11896438
[TBL] [Abstract][Full Text] [Related]
35. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
36. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
37. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
38. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
39. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.
Roy I; Holle L; Song W; Holle E; Wagner T; Yu X
Anticancer Res; 2002; 22(6A):3185-9. PubMed ID: 12530063
[TBL] [Abstract][Full Text] [Related]
40. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
